Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke
Key facts
- Who runs it
- Shandong Provincial Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 432 people, planned
- Started
- 1 Oct 2021
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Edaravone
- Edaravone Dexborneol
- Record updated
- 12 November 2026
Who can take part
- Age
- 35 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Acute anterior circulation ischemic stroke within 48 hours of onset
- Age 35-80 years
- NIHSS score 4-24
- Pre-stroke mRS score ≤1
- Signed informed consent
Who cannot take part
- Intracranial hemorrhage
- Moyamoya disease, vasculitis, or other immune-related infarcts
- Combined tumor, intracranial infection, epilepsy, or severe systemic disease
- History of non-lacunar ischemic stroke within 6 months
- Lacunar infarction or multiple punctate infarcts
- Severe liver or kidney dysfunction
- MRI contraindications
- Participating in other clinical trials
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Acute ischemic stroke
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This multicenter randomized controlled trial evaluates the effect of edaravone dexborneol on blood-brain barrier repair in patients with acute anterior circulation large artery atherosclerotic ischemic stroke within 48 hours of onset.
Read full original descriptionShow less
Patients are randomized 1:1 to receive either edaravone dexborneol (30mg/7.5mg BID IV) or edaravone (30mg BID IV) for 9±2 days, in addition to standard stroke treatment. The primary outcome is the change in blood-brain barrier permeability (Ktrans) measured by DCE-MRI. Secondary outcomes include neurological function scores, serum biomarkers, and safety events.
The 2 groups in the trial
- Control GroupExisting treatment, for comparison
Participants receive edaravone 30mg BID intravenous drip for 9±2 days, plus standard stroke treatment.
Treatment: Edaravone
- Intervention GroupTreatment being tested
Participants receive edaravone dexborneol 30mg/7.5mg BID intravenous drip for 9±2 days, plus standard stroke treatment.
Treatment: Edaravone Dexborneol
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Randomized Controlled Trial Study of the Effect of Edaravone and Dexcamphan on the Repair of Blood-brain Barrier Injury in Acute Infarction of Anterior Circulation
- Criteria questions
- Built from NCT07933692, who can take part
- Record updated
- 12 November 2026